The frequency of pCR in patients was related to PD-L1 expression in cancers and tumor-infiltrating lymphocytes, according to the KEYNOTE-173 [30] study, in which pabrolizumab was used in conjunction with neoadjuvant chemotherapy in patients with high-risk early-stage TNBC. This evidence concerns the gene CD274 and cancer.